AML1-ETO+ AML remains a significant clinical problem, with 30% of patients relapsing and long-term survival rates ranging between 30 and 60%, indicating the need for improved therapeutic approaches [18–19]. This evidence concerns the gene RUNX1 and acute myeloid leukemia.